Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.43 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6621979 | 0.91 | MAPK14 (0.60) | MAPK14PDE10ATGFBR1MAPTL3MBTL1 | |
| SCHEMBL6774532 | 0.89 | MAPT (0.54) | MAPK14MAPTL3MBTL1BRD4BRDT | |
| SCHEMBL6766624 | 0.86 | MAPK14 (0.50) | MAPK14PDE10ABRD4BRDT | |
| SCHEMBL6773835 | 0.85 | MAPK14 (0.55) | MAPK14PDE10AMAPTL3MBTL1 | |
| SCHEMBL6768263 | 0.85 | MAPK14 (0.53) | MAPK14BRD4BRDT | |
| SCHEMBL6767002 | 0.85 | MAPK14 (0.49) | MAPK14PDE10A | |
| SCHEMBL6768077 | 0.84 | MAPK14 (0.65) | MAPK14BRD4BRDT | |
| SCHEMBL6764044 | 0.84 | MAPK14 (0.65) | MAPK14BRD4BRDT | |
| SCHEMBL6767267 | 0.83 | MAPK14 (0.51) | MAPK14TGFBR1BRD4BRDT | |
| SCHEMBL4850491 | 0.83 | MAPK14 (0.59) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6677337-B2 | RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, INFLAMMATORY BOWEL DISEASE, CACHEXIA, SEPTIC SHOCK, CARDIOVASCULAR AND RESPIRATORY SYSTEM DISORDERS | THE PROCTER & GAMBLE COMPANY | 2004-01-13 | — | — | US | claimed |
| US-20030225082-A1 | 1,2-dihydropyrazol-3-ones which controls inflammatory cytokines | PROCTER & GAMBLE COMPANY, THE | 2003-12-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225082-A1 | 1,2-dihydropyrazol-3-ones which controls inflammatory cytokines | IL1B, IL1A, IL1R1 | MAPK14 1086/4885PDE10A 1590/4885TGFBR1 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.